Literature DB >> 408436

Role of protein serotype antigens in protection against disease due to Neisseria meningitidis.

C E Frasch.   

Abstract

Evidence is provided for the protective effects of antibody to noncapsular antigens in immunity to meningococcal disease. Serotype 2 strains were associated with 50% of disease due to group B Neisseria meningitidis in Europe. The amount of serotype antibody in normal individuals is related to age, and adult levels are reached by about 10 years of age. Children under two years of age who have recovered from disease due to groups B and CN. meningitidis of serotype 2 make antibody to serotype 2; this fact indicates the potential immunogenicity of the serotype antigen in young children. The isolated serotype 2 antigen injected into rabbits elicited bactericidal antibody that was only weakly opsonic. Guinea pigs that were infected via spring implants with serotype 2 N. meningitidis developed antibody to serotype 2. After clearance of infection these animals became resistant to challenge with serotype 2 strains of groups B and C N. meningitidis. This serotypes-specific immunity to reinfection persisted for at least four months.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408436     DOI: 10.1093/infdis/136.supplement.s84

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Outer membrane antigens of Neisseria meningitidis group B serotype 2 studied by crossed immunoelectrophoresis.

Authors:  G E Hoff; C E Frasch
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

2.  Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978.

Authors:  E Holten
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

3.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 4.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

5.  Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer membrane proteins.

Authors:  W D Zollinger; R E Mandrell
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

Review 6.  The meningococcus and mechanisms of pathogenicity.

Authors:  I W DeVoe
Journal:  Microbiol Rev       Date:  1982-06

7.  Metabolic analysis of serologically defined Neisseria meningitidis isolates by frequency-pulsed electron capture gas-liquid chromatography.

Authors:  J B Brooks; D S Kellogg; M E Shepherd; D E Craven
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

8.  Distribution of serotypes of Neisseria meningitidis in the Federal Republic of Germany, 1979-1981.

Authors:  U Berger
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

9.  Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

Authors:  G Arakere; C E Frasch
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.

Authors:  J Melancon; R A Murgita; I W Devoe
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.